【3月文獻戰報】Bioss抗體新增高分文獻精彩呈現-商家動態-資訊-生物在線

【3月文獻戰報】Bioss抗體新增高分文獻精彩呈現

作者:北京博奧森生物技術有限公司 2023-05-24T14:03 (訪問量:8413)


截止目前,引用Bioss產品發表的文獻共24676篇,總影響因子115653.06分,發表在Nature, Science, Cell以及Immunity等頂級期刊的文獻共58篇,合作單位覆蓋了清華、北大、復旦、華盛頓大學、麻省理工學院、東京大學以及紐約大學等國際知名研究機構上百所。

我們每月收集引用Bioss產品發表的文獻。若您在當月已發表SCI文章,但未被我公司收集,請致電Bioss,我們將贈予現金鼓勵,金額標準請參考“發文章 領獎金”活動頁面。

近期收錄2023年2月引用Bioss產品發表的文獻共307篇(圖一,綠色柱),文章影響因子(IF) 總和高達2073.152,其中,10分以上文獻42篇(圖二)。

圖一

圖二



本文主要分享引用Bioss產品發表文章至Nature Nanotechnology, Immunity, Cancer Cell等期刊的8IF>15 的文獻摘要讓我們一起欣賞吧。


CELL [IF=66.85]



文獻引用抗體:bs-2735R

Anti-GSTP1 pAb

作者單位:北京大學化學與分子工程學院,北京分子科學國家實驗室,合成與功能生物分子中心

摘要:A generalizable strategy with programmable site specificity for in situ profiling of histone modifications on unperturbed chromatin remains highly desirable but challenging. We herein developed a single-site-resolved multi-omics (SiTomics) strategy for systematic mapping of dynamic modifications and subsequent profiling of chromatinized proteome and genome defined by specific chromatin acylations in living cells. By leveraging the genetic code expansion strategy, our SiTomics toolkit revealed distinct crotonylation (e.g., H3K56cr) and β-hydroxybutyrylation (e.g., H3K56bhb) upon short chain fatty acids stimulation and established linkages for chromatin acylation mark-defined proteome, genome, and functions. This led to the identification of GLYR1 as a distinct interacting protein in modulating H3K56cr′s gene body localization as well as the discovery of an elevated super-enhancer repertoire underlying bhb-mediated chromatin modulations. SiTomics offers a platform technology for elucidating the “metabolites-modification-regulation” axis, which is widely applicable for multi-omics profiling and functional dissection of modifications beyond acylations and proteins beyond histones.

Signal Transduction and

Targeted Therapy [IF=38.104]


文獻引用抗體:bs-1570R

Anti-APOH pAb

作者單位:北京大學基礎醫學院生理學和病理生理學系,分子心血管科學教育部重點實驗室

摘要:Hyperhomocysteinemia (HHcy) is a risk factor for chronic kidney diseases (CKDs) that affects about 85% CKD patients. HHcy stimulates B cells to secrete pathological antibodies, although it is unknown whether this pathway mediates kidney injury. In HHcy-treated 2-kidney, 1-clip (2K1C) hypertensive murine model, HHcy-activated B cells secreted anti-beta 2 glycoprotein I (β2GPI) antibodies that deposited in glomerular endothelial cells (GECs), exacerbating glomerulosclerosis and reducing renal function. Mechanistically, HHcy 2K1C mice increased phosphatidylethanolamine (PE) (18:0/20:4, 18:0/22:6, 16:0/20:4) in kidney tissue, as determined by lipidomics. GECs oxidative lipidomics validated the increase of oxidized phospholipids upon Hcy-activated B cells culture medium (Hcy-B CM) treatment, including PE (18:0/20:4?+?3[O], PE (18:0a/22:4?+?1[O], PE (18:0/22:4?+?2[O] and PE (18:0/22:4?+?3[O]). PE synthases ethanolamine kinase 2 (etnk2) and ethanolamine-phosphate cytidylyltransferase 2 (pcyt2) were increased in the kidney GECs of HHcy 2K1C mice and facilitated polyunsaturated PE synthesis to act as lipid peroxidation substrates. In HHcy 2K1C mice and Hcy-B CM-treated GECs, the oxidative environment induced by iron accumulation and the insufficient clearance of lipid peroxides caused by transferrin receptor (TFR) elevation and down-regulation of SLC7A11/glutathione peroxidase 4 (GPX4) contributed to GECs ferroptosis of the kidneys. In vivo, pharmacological depletion of B cells or inhibition of ferroptosis mitigated the HHcy-aggravated hypertensive renal injury. Consequently, our findings uncovered a novel mechanism by which B cell-derived pathogenic anti-β2GPI IgG generated by HHcy exacerbated hypertensive kidney damage by inducing GECs ferroptosis. Targeting B cells or ferroptosis may be viable therapeutic strategies for ameliorating lipid peroxidative renal injury in HHcy patients with hypertensive nephropathy.


ACS Nano [IF=18.027]


文獻引用抗體:

bs-3884R; Anti-GPX4 pAb | WB

地 址: 北京市通州區馬駒橋鎮聯東U谷西區四期67號樓

聯系人: 秦

電 話: 4009019800

傳 真: 010-58129612

Email:sales@bioss.com.cn

相關咨詢
ADVERTISEMENT